Back to top
more

Orexigen Therapeutics, Inc. (OREX)

(Real Time Quote from BATS)

$0.22 USD

0.22
3,735,420

-0.12 (-34.42%)

Updated Apr 3, 2018 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy

The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.

    Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code

    Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.

      Orexigen Struggles as Contrave Commercialization Costs Rise

      Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

        Implied Volatility Surging for Orexigen (OREX) Stock Options

        Investors in Orexigen Therapeutics (OREX) need to pay close attention to the stock based on moves in the options market lately.

          Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

          Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

            Orexigen's (OREX) Contrave Sales Improving on Promotions

            Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

              The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

              The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

                Why These 4 Biotech Stocks May Not Lose Momentum Soon

                The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.

                  Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress

                  Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.

                    Orexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound?

                    Orexigen (OREX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio

                      Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs

                        Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth

                        On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.

                          Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y

                          Orexigen Therapeutics, Inc.'s (OREX) loss of $4.67 per share in the first quarter of 2017 was significantly wider than the Zacks Consensus Estimate of a loss of $2.60 and the year-ago loss of $1.54.

                            Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y

                            Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.

                              Orexigen Inks Commercialization Deal for Contrave, Stock Up

                              Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.

                                Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU

                                Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.

                                  Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue?

                                  Orexigen Therapeutics, Inc. (OREX) has been on the move lately as the stock has risen by 74.2% in the past four weeks, and it is currently trading well above its 20-Day SMA

                                    Celgene Issues Preliminary 2016 Results, Lifts 2017 View

                                    Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.

                                      Alexion Blood Disorder Drug Gets Orphan Designation in U.S.

                                      Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                                        The Medicines Co LDL-Lowering Drug Positive in Phase II

                                        The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.

                                          VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?

                                          On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).